Pre-earnings options volume in Crispr Therapeutics (CRSP) is normal with calls leading puts 5:2. Implied volatility suggests the market is anticipating a move near 8.9%, or $4.56, after results are released. Median move over the past eight quarters is 4.4%.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRSP Earnings this Week: How Will it Perform?
- Cathie Wood Trims Tesla Stake, Shifts Focus to This Lesser-Known Stock
- Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics today
- Cathie Wood’s ARK Investment bought 34K shares of Crispr Therapeutics today
- AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital